Rosetta Omics
Rosetta Omics is dedicated to advancing precision medicine in oncology through tumor characterization using high-resolution mass spectrometry profiling and AI. Their mission is to help oncologists, clinicians, and pathologists better diagnose, stratify, and rank treatment options for cancer patients from a single tissue slide. They utilize innovative technologies such as MSI, LMD, LC-MS/MS, and AI algorithms to identify biomarkers, predict treatment responses, and discover new therapeutic targets, ultimately aiming to improve patient outcomes and support drug development.
Industries
Nr. of Employees
small (1-50)
Rosetta Omics
Products
Patented conductive-slide tissue analysis method
A patented methodology for using conductive microscope slides to study analytes on tissue sections while preserving protein integrity; intended to support spatial omics workflows.
Patented conductive-slide tissue analysis method
A patented methodology for using conductive microscope slides to study analytes on tissue sections while preserving protein integrity; intended to support spatial omics workflows.
Services
Clinical tumor molecular profiling from biopsy slides
Laboratory service that performs spatial and bulk molecular profiling on biopsy-compatible tissue sections to produce molecular signatures for tumor characterization.
AI-based predictive reporting for treatment ranking
Machine-learning-driven analysis that generates treatment-response predictions and ranks therapeutic options based on a patient’s molecular profile.
Biomarker discovery and drug-target identification services
Discovery services to identify known and novel biomarkers from multi-omics data to support diagnostic validation and therapeutic development.
Clinical tumor molecular profiling from biopsy slides
Laboratory service that performs spatial and bulk molecular profiling on biopsy-compatible tissue sections to produce molecular signatures for tumor characterization.
AI-based predictive reporting for treatment ranking
Machine-learning-driven analysis that generates treatment-response predictions and ranks therapeutic options based on a patient’s molecular profile.
Biomarker discovery and drug-target identification services
Discovery services to identify known and novel biomarkers from multi-omics data to support diagnostic validation and therapeutic development.
Expertise Areas
- Spatial proteomics and metabolomics
- Multi-omics tumor profiling
- Biomarker discovery and validation
- Mass spectrometry-based proteomics
Key Technologies
- Mass spectrometry imaging (MALDI-MSI)
- Liquid chromatography–tandem mass spectrometry (LC-MS/MS)
- Laser capture microdissection
- Label-free quantitative proteomics